Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sorry no response work till 11-11:30 then start tomorrow at 9 and it is busy not slow
buying as results approaching- I see what you mean
I still think that the very small numbers of P patients with good results and some lingering questions over how the exclusions were handled-an AF concern not well addressed by Bertolino- will hurt
I will write to Leo / Bertolino to see if they will say more about it
no reversal possible unless minimal
Nothing to move the stock back up is at hand
let's see how we fare over the cold days of february and march
Not a chance of improvement-
awaits B-OM interim data, and please let the news be good
We could use some good news, right?
NPR WBUR series "this moment in cancer"- interviews and stories with Boston area bigshots(seriously big) in cancer research is just beginning right now with the first part of a weeklong series.
Will we hear anything from ctix?
I applaud your glass half full analysis.
What will happen to CTIX if the glass is glass is half empty?
You are basing a lot on very small numbers
All I can do is repeat- I, for one am thrilled that B-OM will precede P data
Hope, real mostly unfounded but sort of with a basis hope
is it that simple? all about the shorts? Or did AF have a single valid question re elimination of trial participants? How well do we all grasp these crucial exclusions?
Sure I bought more shares, but I do not get all the exclusions.
If you do, please explain- you have the floor
absolutely right
based on a few patients, very small numbers, ctix has abandoned a drug with true proven efficacy in order to pursue a VERY RISKY 2b for prurisol, and to risk a massive amnt of share value in a much riskier- albeit less expensive- clinical trial path( As opposed to doing a phase 3 with B)
climbing right out onto a branch tht could easily break, snap with ugly consequences for us all
are the data robust? For B, sure, absolutely. For P? Uh, no.
could bertolino have responded better? is any bit of what was said a fair critique?
the bit about the LFT's is bogus, as George nicely pointed out
the stuff about an end point of 50 and 100 and 200mg doses not showing a benefit is accurate, but not on point
critique about coming up with numbers of responders after you eliminate a bunch of patients in each sample, and not knowing every little detail about how these patients were excluded- that seems more reasonable to me in terms of a worry, esp since the numbers are very small
bertolino says he signed after seeing the trend for the 200mg patients shown on the slide deck
If it is good enough for him should it be good enough for me, and for you? Hard to be sure. He needed a job after all
I bought a bunch of shares too with this horrendous "buying opportunity".
Hey guess what?
Probably millions of shares still available for purchase under a dollar in the weeks to come as we twist slowly in the wind prior to B-OM interim update
nothing like....averaging down
one was blocked- I see your point
the K blog post!!??! Seriously?
No new info all old news very old news in fact of all the times to post about K this is NOT the time
Get that B OM data out already
of course good that he wants to speed up trials
no guarantee that means results will be any good of course-
dow breaks 20,000
ctix breaks- yeesh
bankruptcy chances? If Prurisol 2b fails and B-OM fails then share price will be nothing or virtually nothing and B will be up for auction again, along with K
I bought more shares, but with real trepidation.
Pretty close to the edge here, aren't we?
re Kevetrin: 2 common drugs and p53
Nature Cell Bio 2016 last author iwakuma High doses of statins can inhibit misfolded p53. Unclear from summary I saw how high the doses would have to be. Very common drugs as you know- many of you prob taking them already. Not of course without side effects
Another recent citation - Cell Reports(author Rangnekar)-about chloroquine and its ability to increase wild type p53 activity
It is just too bad they have NOTHING concrete to release as good news in the face of yet another....buying opportunity.
What if they could put out positive B OM data this week?
Wouldn't it be nice.
And yet the company is treading water, just barely afloat.
do not see this as puff pr
if patients are truly trying to get into the study and there is some chatter about results being good, then I think the news is very good, could not be better in fact. Sure I have been hollering about no control arm and obv that is a problem.
But this is a preliminary study and if Leo is accurate then this is very good news for sure
Now if only he knows anecdotal info about B OM...
K never tested in dosing frequency to show a benefit given short half-life. It remains an unknown. Unless there is something they are not saying.
Too soon to write it off
There is no chance there will be a monster deal for Brilacidin IBD 2017 .
1- IBD is Crohn's and UC. So far only about 6-8 people have gotten any B prep and that is for UP, and not the others. And that is with NO CONTROLS.
2- There would have to be very different approaches for drug delivery for Crohn's and UC
No treatment plan ever mentioned to be in the offing for UC and Crohn's- yet. Sure they have talked about it- but nothing specific talked about. What would the formulation of B be for Crohn's and UC?
3-It is already 2017
No way no how to show some big benefit and make a deal for IBD 2017.
How about 2019?
And for K, 2020? Oh yeah- they would have to start a real trial first.......
Cambridge UK study comparing CA125 and some measure of mutated p53 (from peripheral blood draw) in 40 patients with ovarian CA because they want a better tumor marker to follow response etc. The article in PLoS Medicine 1/17 suggests p53 better than CA125 which they state is slow to respond to changes in tumor size and not always predictive
Can we just start the trial please?
Day after day my google news feed for p53 brings up Aprea articles....never CTIX.
Sigh.
if I write to info@cellceutix I get Leo
What is Menon's email, then?
p53 cancer autoantibodies anyone?
I had never heard of this. Someone out of Madrid in article about Biosensors detect cancer autoantibody for p53 related tumors- they looked at some patients with ovarian and colorectal CA and also at possible very early stage cancer patients as well. They say that autoantibodies are generated against mutant p53 in a subset of patients with p53 mutations, and that these are detectable.
Now there , ladies and gentlemen, is a vision of the future of medicine, and the market for Kevetrin.
You find these people 2-3 years earlier than before and they start taking oral Kevetrin?
I am not saying there is a good chance it will happen-who knows?
But it is interesting.
Gee, if only CTIX Dana Farber had taken the opportunity to give K more frequently 1 or 2 years ago.....
indeed. A puzzle.
More chatter, incl a Brady reference
Presumed actual dialogue, ctix with pharma execs:
Pharma- Hey you guys are just north of Boston, right? How about those Patriots!
CTIX- You know it. And you know what else, as good as the Pats are, our pipeline is even better.
Pharma-Just love those pats, I mean how does Brady keep doing it at 40? Is he 40 yet?
CTIX- Can I tell you about our plans? For the pipeline? It is diverse. I really mean that. And a lot of stuff is just sitting there, on hold, while we do only the limited things that we can do, and maybe a revolutionary cancer treatment and a new class of antibiotic- well those will just have to wait. On the shelf.
Pharma- Oh I get it- just like Brady sitting out the first 4 games. Right. Your products are just...waiting, sort of.
CTIX- yeah like the Brady suspension, kinda. Ha-
Pharma- is that guy 40 yet? wow, what a season.
I wanted to post this since not all of you are right here in the greater Boston metropolitan region.
But I am on it.
It is so exciting, isn't it Let's pretend we can eavesdrop, shall we? On all of these talks...
Big Pharma- Hey cellceutix team, what is shaking?
CTIX-We have some very interesting stuff in the works.
BP- any new results we have not seen?
CTIX- Not just yet, but there is a lot of potential!!
BP- Gee we don't hear that much, now do we. Hey call me when you have some results, OK?
CTIX- Sure- you mean, when we have actual data, right?
BP- Exactly- keep in touch.
Just a sample of some of the very exciting chatter going on even as we speak between our company and large pharmaceutical concerns....
time frame for movement:
B OM they say now end 1Q or start of 2Q
P interim 2Q vs full 3Q- will interim include real info?
B UP more results coming here there
K sliding back who knows?
B generally who knows
OK then set your timer for 3 months best case(OM), more likely 4-8 months until we know about both OM and P. Until then trading to be be more "buying opportunities"
who knows? mgmt says it'll do the trial with IV multi x week
but will they really change it to oral only- and if so- how long would that set the cause back?
We shareholders just need some proof of benefit the soonest way possible, so I would certainly favor the IV trial ASAP.. Esp since it was ALREADY supposed to have started
Me too. Excited, but nervous. CTIX pinning a lot on this trial-
Not that. Not a voice of reason. Saying what must be said- very small numbers for P trial and NO data at higher doses so who knows if it'll do any better or if those doses will fare worse
gosh that really does sound exciting.
I guess when you have an MD and an MBA and whatever else you can really come up with some zingers
not to worry- still almost a week to get K ovarian trial under way for q4 2016
sigh(as if)
would assume neither success nor failure based on v limited data so far
and you think that will happen in the next 6 mos?
Then don't.
Sit on the sidelines.
Load up with no prospect of any 6 months outlook of profit.
Already.
I mean, plenty of buying opportunities, as share price weakness is called here
Tough year, 2016.
company advancing on some fronts, share price despicable.
B- on hold for cellulitis, will we ever see thee, or just an asset dumped in a fire sale if P does not do well?
P- the unloved Charle Brown christmas tree part of the portfolio, for now the centerpiece. One can only hope.
K-the ovarian trial is pending......have you heard that before? don't hold your breath. Oh yeah- we now have, soon to be a part of the portfolio, an oral K, even before we know if K IV even works.
B-UP- maybe a winner
B-OM- maybe
Can interim P results be anything other than, trial proceeds?If that is all the news we can expect then it will be a long year, 2017, twisting slowly in the wind, as we are twisting slowly now, with NO NEWS
Until the fall
It is not a pretty near term look
But of course we are all long term and do not care how much we might have made putting our money elsewhere
Not this again. Really?
They have no way of knowing if it works. The drug has only been given once a week in a few patients, no survival benefit even close to being demonstrated(yeah I know it is phase 1)
They (Menon Leo etc)are as interested in the trial results as we are
Or, how else exactly are you suggesting they know it works?
sorry cannot follow
gee thanks for the tutorial.
This has nothing to do with CART BEFORE THE HORSE
prove it works, already!!!
Look- if they said, all is on hold pending oral use of K instead of IV use that would be OK but BOGUS right?
The othercombo trial drug is IV, so why bother with oral for K?
They need to STAND and DELIVER
Sure oral K is vastly superior. just show that it works(sigh)
the same as the STARTING dose? I doubt it
the same as the final phase 1 dose prob many examples
the question remains- why spend precious time and money on a pill...when no clue if it works?
we have been over the fact that CTIX knew VERY short half life from the beginning
time just keeps slipping away from further K trials........